Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Core Viewpoint - Terns Pharmaceuticals, Inc. is set to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, showcasing its clinical-stage biopharmaceutical developments targeting serious diseases such as oncology and obesity [1]. Company Overview - Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for serious diseases, including oncology and obesity [3]. - The company's pipeline includes three clinical-stage development programs: an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and a THR-β agonist, along with a preclinical GIPR modulator discovery effort prioritizing a GIPR antagonist nomination candidate [3]. Presentation Details - A live webcast of the presentation will be available on the investor relations page of Terns Pharmaceuticals' website, with a replay archived for at least 30 days following the event [2].